journal
MENU ▼
Read by QxMD icon Read
search

Clinical and Experimental Nephrology

journal
https://www.readbyqxmd.com/read/27900568/control-of-phosphate-balance-by-the-kidney-and-intestine
#1
REVIEW
Ichiro Kaneko, Sawako Tatsumi, Hiroko Segawa, Ken-Ichi Miyamoto
The prevention and correction of hyperphosphatemia are major goals of the treatment of chronic kidney disease (CKD)-bone mineral disorders, and thus, Pi balance requires special attention. Pi balance is maintained by intestinal absorption, renal excretion, and bone accretion. The kidney is mainly responsible for the plasma Pi concentration. In CKD, reduced glomerular filtration rate leads to various Pi metabolism abnormalities, and Pi absorption in the small intestine also has an important role in Pi metabolism...
November 30, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27896453/management-of-phosphorus-load-in-ckd-patients
#2
REVIEW
Yutaka Taketani, Fumihiko Koiwa, Keitaro Yokoyama
Disturbances in mineral and bone metabolism play a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term "renal osteodystrophy" has recently been replaced with "CKD-mineral and bone disorder (CKD-MBD)", which includes vascular calcification as well as bone abnormalities. In Japan, proportions of the aged and long-term dialysis patients are increasing which makes management of vascular calcification and parathyroid function increasingly more important...
November 28, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27878657/c3-glomerulopathy-and-current-dilemmas
#3
Naoko Ito, Ryuji Ohashi, Michio Nagata
C3 glomerulopathy (C3G) is a recently identified disease entity caused by dysregulation of the alternative complement pathway, and dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are its components. Because laboratory detection of complement dysregulation is still uncommon in practice, "dominant C3 deposition by two orders greater than that of immunoglobulins in the glomeruli by immunofluorescence", as stated in the consensus report, defines C3G. However, this morphological definition possibly includes the cases with glomerular diseases of different mechanisms such as post-infectious glomerulonephritis...
November 23, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27873037/the-true-distribution-volume-and-bioavailability-of-mizoribine-in-children-with-chronic-kidney-disease
#4
Takuhito Nagai, Osamu Uemura, Hisashi Kaneda, Katsumi Ushijima, Kazuhide Ohta, Yoshimitsu Gotoh, Kenichi Satomura, Masaki Shimizu, Mikiya Fujieda, Masashi Morooka, Takuji Yamada, Masayoshi Yamada, Naohiro Wada, Yukiya Hashimoto
BACKGROUND: Mizoribine (MZR) is used kidney transplant and various kidney diseases. However, few studies reported the association between pharmacokinetics and pharmacodynamics. The Pharmacokinetics Study Group for Pediatric Kidney Disease (PSPKD) used population pharmacokinetics (PPK) analysis and Bayesian analysis to investigate the usefulness of MZR. In this study, the fact that almost all MZR are excreted unchanged in urine was used to calculate its bioavailability (F) and true distribution volume (V d), and analyzed these correlation with age...
November 21, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27848058/current-pathological-perspectives-on-chronic-rejection-in-renal-allografts
#5
REVIEW
Shigeo Hara
Chronic rejection in renal transplantation clinically manifests as slow deterioration in allograft function and is a major contributor of late renal graft loss. Most cases of chronic rejection involve chronic antibody-mediated rejection (ABMR) triggered by the interaction of donor-specific alloantibodies with endothelial cells of the microcirculation. The evolution of the Banff classification involved a major revision of the ABMR criteria during the 2000s and led to the inclusion of detailed pathological characteristics of chronic ABMR in the 2013 Banff scheme, including microcirculation damage observed as newly formed basement membranes and arterial fibrous intimal proliferation...
November 16, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27844184/possible-prevention-of-uremic-nausea-by-vitamin-d-receptor-activators-in-non-dialysis-patients-with-stage-5-chronic-kidney-disease
#6
Masato Ikeda, Yoshimi Ueda, Yukio Maruyama, Keitaro Yokoyama, Takashi Yokoo, Nobuhiko Joki, Ryoichi Ando, Toshio Shinoda, Daijo Inaguma, Toshihiko Yamaka, Yasuhiro Komatsu, Fumihiko Koiwa, Toshifumi Sakaguchi, Shigeo Negi, Takashi Shigematsu
BACKGROUND: Nausea is a major uremic symptom and a frequent indication for starting dialysis. However, preventive medication for uremic nausea has not yet been identified. Vitamin D receptor activators (VDRAs) may prevent uremic nausea via their pleiotropic actions. The objective of this study was to explore whether VDRA administration during the predialysis period is associated with a reduced prevalence of uremic nausea just prior to beginning dialysis. METHODS: A multicenter, retrospective, cross-sectional study was performed to identify a medication to prevent uremic nausea...
November 14, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27838783/the-fgf23-and-klotho-system-beyond-mineral-metabolism
#7
REVIEW
Makoto Kuro-O
FGF23 is a bone-derived hormone that acts primarily on the kidney to induce phosphaturia and suppress synthesis of 1,25-dihydroxyvitamin D3. The unique feature of FGF23 is that it requires Klotho as an obligate co-receptor. The FGF23-Klotho system has emerged as an endocrine axis indispensable for maintaining phosphate homeostasis. Mineral and bone disorders associated with chronic kidney disease (CKD-MBD) can be viewed as a series of events triggered by a compensatory response of the FGF23-Klotho system to excess phosphate intake relative to the residual nephron number...
November 12, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27832343/erratum-to-dose-response-efficacy-and-safety-of-pa21-in-japanese-hemodialysis-patients-with-hyperphosphatemia-a-randomized-placebo-controlled-double-blind-phase-ii-study
#8
Fumihiko Koiwa, Akira Terao
No abstract text is available yet for this article.
November 10, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27830351/antineutrophil-cytoplasmic-antibody-associated-glomerulonephritis-with-immunoglobulin-deposition
#9
Orie Hirose, Mitsuyo Itabashi, Takashi Takei, Kazuho Honda, Kosaku Nitta
BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is commonly classified as pauci-immune glomerulonephritis; however, some cases have granular immunoglobulin deposition along the glomerular capillary. The pathogenesis of immune deposits is poorly studied. METHODS: Of 66 patients diagnosed with ANCA-associated glomerulonephritis on renal biopsy, cases with immunoglobulin deposition along the glomerular capillary were identified and their clinicopathological characteristics were analyzed...
November 9, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27815652/mesangial-proliferative-glomerulonephritis-in-murine-malaria-parasite-plasmodium-chabaudi-as-infected-nc-mice
#10
Akihito Yashima, Masashi Mizuno, Yukio Yuzawa, Koki Shimada, Norihiko Suzuki, Hideo Tawada, Waichi Sato, Naotake Tsuboi, Shoichi Maruyama, Yasuhiko Ito, Seiichi Matsuo, Tamio Ohno
BACKGROUND: Malaria is an important tropical disease and has remained a serious health problem in many countries. One of the critical complications of malarial infection is renal injury, such as acute renal failure and chronic glomerulopathy. Few animal models of nephropathy related to malarial infection have been reported. Therefore, we developed and investigated a novel malarial nephropathy model in mice infected by murine malaria parasites. METHODS: NC mice and C57BL/6J mice were infected with Ttwo different murine malaria parasites, Plasmodium (P...
November 4, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27812762/minimal-change-nephrotic-syndrome-and-prohibitin-2-gene-polymorphism
#11
Keisuke Sugimoto, Tomoki Miyazawa, Kohei Miyazaki, Hidehiko Yanagida, Takuji Enya, Hitomi Nishi, Norihisa Wada, Mitsuru Okada, Tsukasa Takemura
BACKGROUND: Patients with minimal change nephrotic syndrome (MCNS) often also have allergic diseases. Abnormalities of Th2-derived cytokines and T-cell functions contribute to development of these diseases. On the other hand, imbalances between reactive oxygen species (ROS) and antioxidants have been implicated in MCNS and progression of atopic dermatitis. ROS, produced mainly within mitochondria, subject cells to oxidative stress, while prohibitin 2 protects mitochondria by increasing tolerance to ROS...
November 4, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27796712/female-x-linked-alport-syndrome-with-somatic-mosaicism
#12
Kana Yokota, Kandai Nozu, Shogo Minamikawa, Tomohiko Yamamura, Keita Nakanishi, Hisashi Kaneda, Riku Hamada, Yoshimi Nozu, Akemi Shono, Takeshi Ninchoji, Naoya Morisada, Shingo Ishimori, Junya Fujimura, Tomoko Horinouchi, Hiroshi Kaito, Koichi Nakanishi, Ichiro Morioka, Mariko Taniguchi-Ikeda, Kazumoto Iijima
BACKGROUND: X-linked Alport syndrome (XLAS) is a progressive, hereditary nephropathy. Although males with XLAS usually develop end-stage renal disease before 30 years of age, some men show a milder phenotype and possess somatic mosaic variants of the type IV collagen α5 gene (COL4A5), with severity depending on variant frequencies. In females, somatic mosaic variants are rarely reported in XLAS, and it is not clear what determines severity. METHODS: Two females with somatic mosaic mutations in COL4A5 with variant frequencies of 17...
October 31, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27796711/heterozygous-fabry-disease-complicated-by-acute-onset-paralysis
#13
Yoichi Iwafuchi, Yuko Oyama, Ichiei Narita
No abstract text is available yet for this article.
October 31, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27783276/mizoribine-therapy-combined-with-steroids-and-mizoribine-blood-concentration-monitoring-for-idiopathic-membranous-nephropathy-with-steroid-resistant-nephrotic-syndrome
#14
Takao Saito, Masayuki Iwano, Koichi Matsumoto, Tetsuya Mitarai, Hitoshi Yokoyama, Noriaki Yorioka, Shinichi Nishi, Ashio Yoshimura, Hiroshi Sato, Satoru Ogahara, Yoshie Sasatomi, Yasufumi Kataoka, Shiro Ueda, Akio Koyama, Shoichi Maruyama, Masaomi Nangaku, Enyu Imai, Seiichi Matsuo, Yasuhiko Tomino
BACKGROUND: We designed a prospective and randomized trial of mizoribine (MZR) therapy combined with prednisolone (PSL) for idiopathic membranous nephropathy (IMN) with steroid-resistant nephrotic syndrome (SRNS). METHODS: Patients with IMN were divided into 2 groups, and MZR combined with PSL was administered for 2 years. PSL was initially prescribed at 40 mg/day and tapered. MZR was given once-a-day at 150 mg and 3-times-a-day at 50 mg each to groups 1 and 2...
October 25, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27783275/a-new-peritoneal-dialysis-fluid-for-japanese-patients-a-randomized-non-inferiority-clinical-trial-of-safety-and-efficacy
#15
Masaaki Nakayama, Yoshindo Kawaguchi, Takashi Akiba, Masao Kim, Hidemune Naito, Shigeko Hara, Teruhiko Maeba, Noriaki Yorioka, James A Sloand, Mark R Marshall
BACKGROUND: We report here two new peritoneal dialysis fluids (PDFs) for Japan [BLR 250, BLR 350 (Baxter Limited, Japan)]. The PDFs use two-chamber systems, and have bicarbonate and lactate buffer to a total of 35 mmol/L. In separate trials, the new PDFs were compared to two "standard" systems [PD-4, PD-2 (Baxter Limited, Japan)]. The trials aimed to demonstrate non-inferiority of peritoneal creatinine clearance (pCcr), peritoneal urea clearance (pCurea) and ultrafiltration volume (UF), and compare acid-base and electrolyte balance...
October 25, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27771774/usefulness-of-combination-therapy-with-daclatasvir-plus-asunaprevir-in-chronic-hepatitis-c-patients-with-chronic-kidney-disease
#16
Norihiko Morisawa, Yohei Koshima, Jun-Ichi Satoh, Yukio Maruyama, Satoru Kuriyama, Takashi Yokoo, Morimasa Amemiya
AIM: Combination therapy with Daclatasvir (DCV) plus Asunaprevir (ASV) has been proven effective in patients with chronic hepatitis C virus (HCV) infection. However, little is known as to the effect of this therapy in patients with reduced renal function. Focusing on CKD patients whose renal function has declined, the present trial addresses the efficacy and safety of this combination therapy in CKD patients with reduced estimated glomerular filtration rate (eGFR). MATERIALS AND METHODS: The study design is a single-center, retrospective longitudinal observational study enrolling 106 patients with (n = 29) or without (n = 77) CKD...
October 22, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27770292/the-potential-role-of-perivascular-lymphatic-vessels-in-preservation-of-kidney-allograft-function
#17
Akihiro Tsuchimoto, Toshiaki Nakano, Shoko Hasegawa, Kosuke Masutani, Yuta Matsukuma, Masahiro Eriguchi, Masaharu Nagata, Takehiro Nishiki, Hidehisa Kitada, Masao Tanaka, Takanari Kitazono, Kazuhiko Tsuruya
BACKGROUND: Lymphangiogenesis occurs in diseased native kidneys and kidney allografts, and correlates with histological injury; however, the clinical significance of lymphatic vessels in kidney allografts is unclear. METHODS: This study retrospectively reviewed 63 kidney transplant patients who underwent protocol biopsies. Lymphatic vessels were identified by immunohistochemical staining for podoplanin, and were classified according to their location as perivascular or interstitial lymphatic vessels...
October 21, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27761671/preemptive-kidney-transplantation-a-propensity-score-matched-cohort-study
#18
Masayoshi Okumi, Yasuyuki Sato, Kohei Unagami, Toshihito Hirai, Hideki Ishida, Kazunari Tanabe
BACKGROUND: The reasons for improved outcomes associated with preemptive kidney transplantation (PKT) are incompletely understood, and post-transplant complications have been scarcely investigated. METHODS: We evaluated the outcomes of PKT in both unmatched (n = 1060) and propensity score matched cohorts (n = 186) of adults who underwent living kidney transplant between 2000 and 2014. Outcomes were estimated glomerular filtration rate (eGFR), biopsy-proven rejection, cytomegalovirus (CMV) infection, post-transplant diabetes mellitus (PTDM), cardiovascular disease (CVD), graft failure (non-censored for death), and malignancy...
October 19, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27761670/the-association-between-urinary-liver-type-fatty-acid-binding-protein-and-chronic-kidney-disease-classification-in-hiv-infected-japanese-patients
#19
Shinichi Hikasa, Megumi Yasuda, Kyoko Hideta, Mai Kawakami, Satoshi Higasa, Akihiro Sawada, Tazuko Tokugawa, Takeshi Kimura
BACKGROUND: Renal dysfunction is recognized with increasing frequency among the noninfectious comorbidities associated with human immunodeficiency virus (HIV) infection. Urinary liver-type fatty acid-binding protein (L-FABP) has been shown to be a new biomarker to screen for not only tubulointerstitial damage but also kidney dysfunction. METHODS: We performed a cross-sectional study to determine the association between the urinary L-FABP and chronic kidney disease (CKD) among 77 HIV-infected Japanese patients by backward-stepwise multivariable logistic regression...
October 19, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27757709/idiopathic-pre-capillary-pulmonary-hypertension-in-patients-with-end-stage-kidney-disease-effect-of-endothelin-receptor-antagonists
#20
Masato Nishimura, Toshiko Tokoro, Satoru Yamazaki, Tetsuya Hashimoto, Hiroyuki Kobayashi, Toshihiko Ono
BACKGROUND: We examined the prevalence, prognosis, and effect of endothelin receptor antagonists on survival in end-stage kidney disease patients with idiopathic pre-capillary pulmonary hypertension. METHODS: We investigated 1988 end-stage kidney disease patients in Toujinkai Hospital from January 1, 2001 to December 31, 2014. Pulmonary hypertension was screened by symptoms (dyspnea, hypotension, or near syncope) and echocardiography, and diagnosed by computed tomography with enhancement, pulmonary flow scintigraphy, and right heart catheterization...
October 19, 2016: Clinical and Experimental Nephrology
journal
journal
32795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"